Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (17,200,287)	$ (2,956,731)
Adjustments to reconcile net loss to Net cash used in operating activities:
Stock based compensation	4,626,529	179,344
Amortization of operating lease right-of-use asset	39,492
Depreciation	44,291
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	657,341	(25,681)
Accounts payable	199,553	(79,248)
Accrued expenses	(1,230,608)	172,569
Right-of-use liability	(15,401)
Net cash used in operating activities	(12,879,090)	(2,709,747)
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.	3,718,742
Purchase of property and equipment	(241,195)	(103,738)
Net cash provided by/(used in) investing activities	3,477,547	(103,738)
Cash flows from financing activities:
Proceeds from - ArTara Private Placement, net of offering costs	1,867,580
Proceeds from - Proteon Private Placement, net of offering costs	12,413,337
Proceeds from - Series 1 Convertible Preferred Stock, net of offering costs	25,318,706
Repayments under short-term debt	(741,587)
Net cash provided by financing activities	38,858,036
Net increase/(decrease) in cash and cash equivalents and restricted cash	29,456,493	(2,813,485)
Cash and cash equivalents and restricted cash - beginning of year	564,124	5,549,952
Cash and cash equivalents and restricted cash - end of year	30,020,617	2,736,467
Cash paid for:
Interest	15,059
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses	121,712
Purchase of insurance agreement with notes payable	1,668,570
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.	$ 34,532,627